Merus reports positive financial results and progress in clinical trials for cancer treatments

From GlobeNewswire: 2024-10-31 08:08:00

Merus N.V. is conducting Phase 3 trials for petosemtamab in head and neck cancer. Interim clinical data showed promising results. The company’s cash, cash equivalents, and securities are expected to fund operations until 2028. Petosemtamab, Zeno, MCLA-129, and MCLA-145 are being investigated for various cancers. Collaborations with Incyte, Eli Lilly, Gilead, and Ono are progressing well. The FDA has accepted the BLA for Zeno in lung and pancreatic cancer for priority review.

In the third quarter, Merus dosed patients in trials for MCLA-129 and MCLA-145. Financially, collaboration revenue increased, while expenses also rose. The company’s cash situation is solid, with $782.9 million in cash, cash equivalents, and securities. Merus remains optimistic about the future of its product candidates and collaborations.

Merus N.V. is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, known as Multiclonics®. Forward-looking statements indicate potential risks and uncertainties, including funding needs, regulatory delays, and reliance on third parties. The company’s patents, trademarks, and collaborations are key to its future success. Multiclonics®, Biclonics®, and Triclonics® are registered trademarks of Merus N.V.



Read more at GlobeNewswire:: Merus Announces Financial Results for the Third Quarter